Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Conjugate Vaccine Market Grown from 2024 to 2025?

In recent times, there has been a sharp increase in the size of the conjugate vaccine market. This market is projected to expand from a value of $18.9 billion in 2024 to a worth of $21.46 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.5%. This growth during the historic period can be credited to several factors including the prevalence of disease, government-run immunization initiatives, heightened awareness, a focus on pediatric vaccination, and emerging trends in preventive healthcare.

What Growth Rate Is Anticipated for the Conjugate Vaccine Market in the Coming Years?

In the coming years, the conjugate vaccine market is projected to experience significant expansion, reaching a valuation of “$34.59 billion in 2029 and registering a compound annual growth rate (CAGR) of 12.7%. Factors contributing to this growth during the forecast period include broader immunization policies, changes in population ages, new indications for vaccines, global health and safety issues, international cooperation, and the influence of economic development. Key trends during the forecast period encompass joint efforts for vaccine distribution, strategic approaches for populations at high-risk, utilization in upcoming infectious diseases, advances in vaccine production technologies, and worldwide health initiatives for equal vaccine distribution.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

Who Are the Leading Companies in the Conjugate Vaccine Market?

Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

What Are the Key Drivers of the Conjugate Vaccine Market?

The growth of the conjugate vaccine market is anticipated to be driven by the rising usage of these vaccines among adults. Conjugate vaccines, designed to generate a potent immune response against bacterial capsular polysaccharides, boost the human body’s protective barrier against bacterial infections. They help lower the chances of severe illness, complications, and the spread of these bacterial diseases by instigating a formidable immune response in adults. For example, a report by the UK Health Security Agency (UKHSA), a public health agency based in the UK, in June 2024 confirmed that the 12-month coverage of the ‘6-in-1’ vaccine in the UK remained stable at 91.7%. The initial dose of the pneumococcal conjugate vaccine (PCV) persisted at 93.7%. The coverage of the Rotavirus saw a rise of 0.6%, reaching 89.3%, and the second dose of the meningitis B vaccine (MenB2) saw a small increase of 0.1%, hitting 91.5%. As such, the higher uptake of conjugate vaccines among adults is fueling the expansion of the conjugate vaccine market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10850&type=smp

What Are the Key Market Segments in the Conjugate Vaccine Industry?

The conjugate vaccine market covered in this report is segmented –

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine

2) By Pathogen: Bacterial, Viral

3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid

4) By Patient: Pediatric, Adults

5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:

1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines

2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

What Are the Latest Trends in the Conjugate Vaccine Market?

The development of novel conjugate vaccines is becoming a prominent trend in the conjugate vaccine market. Firms in this market are focusing their efforts on creating groundbreaking conjugate vaccines to maintain market dominance. For example, Pfizer Inc., an American pharmaceutical and biotech company, launched Prevnar 20 in Canada in June 2022. Prevnar 20 is a pneumococcal 20-valent conjugate vaccine designed to protect adults 18 years and older from pneumonia and invasive pneumococcal diseases. In addition to the 13 serotypes already included in PREVNAR 13, Prevnar 20 contains conjugates for seven more serotypes, known for their connection with invasive pneumococcal disease, high case-fatality rates, antibiotic resistance, and meningitis.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

What Are the Key Regional Markets in the Conjugate Vaccine Industry?

North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10850

This Report Delivers Insight On:

1. How big is the conjugate vaccine market, and how is it changing globally?

2. Who are the major companies in the conjugate vaccine market, and how are they performing?

3. What are the key opportunities and risks in the conjugate vaccine market right now?

4. Which products or customer segments are growing the most in the conjugate vaccine market?

5. What factors are helping or slowing down the growth of the conjugate vaccine market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model